Hernandez-Molina G.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Michel-Peregrina M.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Hernandez-Ramirez D.F.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Sanchez-Guerrero J.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Llorente L.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N
Rheumatology | Year: 2011
Objective. To assess the saliva levels of CXCL13, CXCL10, CCL2, CCL3, CXCL12 and CCL5 in patients with primary SS (pSS), patients with associated SS (aSS), patients with systemic autoimmune disease (SAD) without SS, pre-clinical SS and healthy controls. Methods. We included 44 patients with pSS (Group A), 30 with aSS (Group B), 49 with SAD without SS (Group C), 14 patients with SAD and focal lip infiltrates, but who do not fulfil SS criteria (Group D, pre-clinical SS) and 32 healthy controls (Group E). Saliva samples were collected and analysed for chemokine levels by luminometry. We used descriptive statistics and the Mann-Whitney U-test and Kruskall-Wallis test. Results. All the studied chemokines were found at low concentration in controls with the exception of CCL2. Patients with pSS had higher levels CXCL10 and CCL2 than controls (P = 0.05). However, they had similar levels of CXCL13, CCL5, CXCL12, CCL2 and CXCL10 than patients with aSS and SAD without SS. Patients with pre-clinical SS had higher levels of CXCL10 than patients with pSS (P = 0.03), aSS (P = 0.04) and controls (P = 0.001). CCL2 levels were higher in all patients with an autoimmune background when compared with controls (P<0.05 for each comparison). Conclusion. We found no difference in salivary chemokines between patients neither with pSS or aSS nor in patients with SAD. CCL2 and CXCL10 were increased in all patients with an autoimmune background. CXCL10 was notably increased in pre-clinical SS, suggesting it could be an early inflammatory salivary biomarker. © The Author 2011. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.
Morales-Buenrostro L.E.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Salas-Nolasco O.I.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Barrera-Chimal J.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Barrera-Chimal J.,Unidad University |
And 6 more authors.
PLoS ONE | Year: 2014
Background and Objectives: Acute kidney injury (AKI) complicates the course of disease in critically ill patients. Efforts to change its clinical course have failed because of the fail in the early detection. This study was designed to assess whether heat shock protein (Hsp72) is an early and sensitive biomarker of acute kidney injury (AKI) compared with kidney injury molecule (Kim-1), neutrophil gelatinase-associated lipocalin (NGAL), and interleukin-18 (IL-18) biomarkers.Methods: A total of 56 critically ill patients fulfilled the inclusion criteria. From these patients, 17 developed AKI and 20 were selected as controls. In AKI patients, Kim-1, IL-18, NGAL, and Hsp72 were measured from 3 days before and until 2 days after the AKI diagnosis and in no-AKI patients at 1, 5 and 10 days after admission. Biomarker sensitivity and specificity were determined. To validate the results obtained with ROC curves for Hsp72, a new set of critically ill patients was included, 10 with AKI and 12 with no-AKI patients.Results: Urinary Hsp72 levels rose since 3 days before the AKI diagnosis in critically ill patients; this early increase was not seen with any other tested biomarkers. Kim-1, IL-18, NGAL, and Hsp72 significantly increased from 2 days before AKI and remained elevated during the AKI diagnosis. The best sensitivity/specificity was observed in Kim-1 and Hsp72: 83/95% and 100/90%, respectively, whereas 1 day before the AKI diagnosis, the values were 100/100% and 100/90%, respectively. The sensibility, specificity and accuracy in the validation test for Hsp72 were 100%, 83.3% and 90.9%, respectively.Conclusions: The biomarker Hsp72 is enough sensitive and specific to predict AKI in critically ill patients up to 3 days before the diagnosis. ©2014 Morales-Buenrostro et al.
Cruz-Bautista I.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Mehta R.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Cabiedes J.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
Garci a-Ulloa C.,Instituto Nacional Of Ciencias Me Dicas Y Nutricio N Salvador Zubira N |
And 4 more authors.
Clinica Chimica Acta | Year: 2014
Background: In familial combined hyperlipidemia (FCHL) the severity of the dyslipidemia is determined by an overproduction of VLDL (very low density lipoprotein) particles and by its abnormal lipid composition. However, few are known regarding the metabolic factors that determine these abnormalities. We investigated the impact of metabolic factors on the number of atherogenic particles (apolipoprotein B level (apoB)) and the triglyceride content of very low-density lipoproteins (VLDLs-TG). Methods: A cross-sectional study done in FCHL subjects and gender and age-matched healthy subjects. A clinical assessment, lipid profile and plasma concentrations of insulin, apolipoprotein CIII (apo CIII), apolipoprotein AII (apo AII), high sensitive C-reactive protein (HS-CRP), adiponectin and leptin were documented in 147 FCHL patients and 147 age-matched healthy subjects. Multivariate regression models were performed to investigate the independent determinants of VLDL-TG and apo B levels adjusting for confounding factors. Results: The variables that determined the VLDL-triglyceride content as a surrogate of VLDL composition were apo CIII (β = 0.365, p. <. 0.001), insulin (β = 0.281, p. <. 0.001), Apo AII (β = 0.145, p. <. 0.035), and adiponectin levels (β = - 0.255, p. <. 0.001). This model explained 34% of VLDL composition (VLDL-TG) variability. However, none of these variables were independent contributors of apo B-containing particles. Conclusions: In patients with FCHL apo CIII, apo AII and adiponectin are major novel factors determining the VLDL particle composition. However, such factors do not explain apo B-containing particles. © 2014.